Denteric is pleased to advise that it has completed recruitment and dosing of 3 cohorts in its Phase I GPV381 clinical trial. This first in human study is assessing the safety of GPV381 in healthy volunteers that have been confirmed as positive for the bacterium Porphyromonas gingivalis. Three cohorts have been tested at three ascending dose levels and all eligible participants have completed dosing with the vaccine, which appears to be well tolerated with no safety concerns. The company is now planning an additional cohort in people with confirmed periodontal disease.
Denteric completes recruitment for Phase I clinical trial in Healthy Volunteers
